Share this article
Share this article
HACKENSACK, N.J., March 10, 2021 /PRNewswire/ Convalescent plasma, the use of survivors antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels of antibodies, according to a new publication by scientists at Hackensack Meridian
Health, New Jersey s largest and most comprehensive health network.
The treatment was safe, transferred the survivors antibodies, and did not prevent the recipients from making their own antibodies, according to the results published recently in the journal We have developed this technique and methodology to save the lives of patients, said Michele Donato, M.D., FACP, CPE, chief of Stem Cell Transplantation and Cellular Therapy at John Theurer Cancer Center at Hackensack University Medical Center, and who is leading the study. We believe our hard work is paying off.
CBS News
Convalescent plasma research featured on 60 Minutes shows promise in new scientific study
In May 2020, 60 Minutes reported on a study researching the use of high-antibody blood plasma to help treat hospitalized COVID-19 patients. Newly published results show hope for the therapy. 2021 Mar 10
With the COVID-19 pandemic having entered its second year as a paramount threat to global public health, scientific bets placed during the earlier days of the medical battle are starting to pay off. Little more than a year after the discovery of the novel coronavirus in Wuhan, China, frenzied scientific inquiries are reporting out results.
In May 2020, 60 Minutes reported on one such project in a story we called, The Promise of Plasma. Correspondent Bill Whitaker profiled the work of Dr. Michele Donato, the chief of stem cell transplantation and cellular therapy at Hackensack Meridian Health s John Theurer Cancer Center in northern New Jersey
A new Hackensack Meridian Health study shows that people with mild symptoms of COVID-19 may be helped by a controversial drug that had been widely used in the early days of the pandemic before several studies questioned its benefits and safety.
The recently published study looked at a group of people treated as outpatients last year and found that those who received an anti-inflammatory drug, hydroxychloroquine, which is often used for malaria, were significantly less likely to end up in the hospital. Doctors who conducted the study say the findings suggest that it should be tested further. We make it clear we can t recommend it to be given, said Andrew Ip, a lymphoma physician and director of the Division of Outcomes and Value Research at the
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary
Outcomes Matter Innovations, LLC (OMI) Announces Promotions of Four Members of Senior Management Team
News provided by
Share this article
Share this article
JERSEY CITY, N.J., Jan. 7, 2021 /PRNewswire/ Outcomes Matter Innovations, LLC (OMI), a Jersey City based leader in technology enablement that facilitates a new business model in Value-Based Care Reimbursement for Specialty physicians, as well as management services for established healthcare providers throughout the Northeast, is excited to announce the promotion of four members of their senior management team.
Brenda Hurtubise, MPA, has been named President of OMI, as part of the organizational restructuring. In her new role, Ms. Hurtubise will lead the management services division, primarily responsible for driving operational efficiencies while improving the overall patient experience for hospitals and physician practices. With over 20 years of experience in healthcare operations, Ms. Hurtubise assumes this role a